Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27740459 | 0.98 | NFE2L2 (0.46) | NFE2L2LMNASMN1; SMN2PTGS2PTGS1 | |
| SCHEMBL11577997 | 0.96 | NFE2L2 (0.45) | NFE2L2LMNASMN1; SMN2PTGS2PTGS1 | |
| SCHEMBL3839152 | 0.84 | NFE2L2 (0.42) | NFE2L2SMN1; SMN2PTGS2KDM4EALDH1A1 | |
| SCHEMBL27669602 | 0.83 | ALDH1A1 (0.45) | NFE2L2SMN1; SMN2PTGS2KDM4EALDH1A1 | |
| SCHEMBL19275104 | 0.82 | EPAS1 (0.43) | NFE2L2LMNAPTGS2PTGS1KDM4E | |
| SCHEMBL27669603 | 0.82 | ALDH1A1 (0.44) | NFE2L2SMN1; SMN2PTGS2KDM4EALDH1A1 | |
| SCHEMBL10559419 | 0.80 | LMNA (0.45) | NFE2L2LMNASMN1; SMN2PTGS2PTGS1 | |
| SCHEMBL28479379 | 0.80 | ELANE (0.61) | NFE2L2LMNASMN1; SMN2PTGS2PTGS1 | |
| SCHEMBL10582499 | 0.79 | NFE2L2 (0.45) | NFE2L2LMNASMN1; SMN2PTGS2PTGS1 | |
| SCHEMBL27752732 | 0.79 | NFE2L2 (0.45) | NFE2L2KDM4EALDH1A1KCNH2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025132148-A1 | ADJUVANT COMPOSITIONS FOR AGROCHEMICAL APPLICATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2025-06-26 | — | — | WO | disclosed |
| US-20240158424-A1 | METHOD FOR PRODUCING DIPHOSPHINE MONOXIDE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2024-05-16 | — | — | US | disclosed |
| EP-4361162-A2 | METHOD FOR PRODUCING DIPHOSPHINE MONOXIDE | Takasago International Corporation (JP) | 2024-05-01 | — | — | EP | disclosed |
| CN-116742135-A | High-voltage electrolyte for lithium battery | 浙江大学 | 2023-09-12 | — | — | CN | disclosed |
| CN-112839505-B | Phenylpyrazole compound and method for controlling plant disease | 住友化学株式会社 | 2023-06-06 | — | — | CN | disclosed |
| EP-3679035-A1 | NOVEL FUNGICIDAL HETEROCYCLIC COMPOUNDS | PI Industries Ltd. (IN) | 2020-07-15 | — | — | EP | disclosed |
| WO-2019048989-A1 | NOVEL FUNGICIDAL HETEROCYCLIC COMPOUNDS | PI INDUSTRIES LTD. (IN) | 2019-03-14 | — | — | WO | disclosed |
| WO-2018193387-A1 | HETEROCYCLIC COMPOUNDS WITH MICROBIOCIDAL PROPERTIES | PI INDUSTRIES LTD. (IN) | 2018-10-25 | — | — | WO | disclosed |
| WO-2014124850-A1 | SUBSTITUTED [1,2,4]TRIAZOLE AND IMIDAZOLE COMPOUNDS | BASF SE (DE) | 2014-08-21 | — | — | WO | disclosed |
| US-8293905-B2 | Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-23 | — | — | US | disclosed |
| US-8088883-B2 | Transition metal complex and process for producing conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-02-24 | — | — | US | disclosed |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-07-22 | — | — | US | disclosed |
| EP-2192124-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND WITH THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| EP-2172470-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158424-A1 | METHOD FOR PRODUCING DIPHOSPHINE MONOXIDE | TDO2, SCO2, DUOX1 | NFE2L2 842/4885LMNA 4739/4885SMN1; SMN2 3749/4885 |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP1M1 | NFE2L2 77/4885LMNA 2664/4885SMN1; SMN2 3838/4885 |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP2M1 | NFE2L2 380/4885LMNA 3345/4885SMN1; SMN2 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.